Corbus Pharmaceuticals Holdings (CRBP) Cash from Financing Activities (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $2.9 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities fell 88.62% year-over-year to $2.9 million; the TTM figure through Sep 2025 stood at $2.8 million (down 98.28% YoY), while the FY2024 annual figure was $166.6 million, up 6004.93% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $2.9 million, up from -$13000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $106.6 million in Q1 2024, with the low at -$1.9 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$13000.0 (2024), against an average of $13.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 912.98% in 2023, then soared 194042.14% in 2024.
• Corbus Pharmaceuticals Holdings' Cash from Financing Activities stood at $767938.0 in 2021, then sank by 69.49% to $234322.0 in 2022, then tumbled by 912.98% to -$1.9 million in 2023, then surged by 99.32% to -$13000.0 in 2024, then jumped by 22030.77% to $2.9 million in 2025.
• Business Quant data shows CRBP's Cash from Financing Activities at $2.9 million in Q3 2025, -$13000.0 in Q4 2024, and $25.0 million in Q3 2024.